Advertisement
Screener

Pyxis Oncology, Inc. (PYXS) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Pyxis Oncology, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Pyxis Oncology, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $63.50M went out.
  • Fiscal year ended 2025-12-31: from investing, $58.86M came in.
  • Fiscal year ended 2025-12-31: from financing, $594.00K came in.
  • Fiscal year ended 2025-12-31: change in cash, $4.05M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2025-12-31-$63.50M$58.86M-$148.00K$632.00K-$4.05M
2024-12-31-$57.67M$8.15M-$240.00K$296.00K$59.27M*$9.81M
2023-12-31-$70.71M-$104.85M-$445.00K$120.00K$6.25M*-$169.63M
2022-12-31-$89.33M-$6.40M$183.00K-$95.55M
2021-12-31-$35.33M-$590.00K$167.00K$303.88M*$268.13M
2020-12-31-$10.08M-$1.48M$3.00K-$11.53M

Each quarter (3 month)

Quarter endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$18.21M*$21.30M*-$53.00K*$10.05M*
2026-03-31-$26.00M$16.37M-$25.00K-$9.66M
2025-12-31-$10.43M*$16.26M*-$71.00K*$740.00K*
2025-09-30-$13.28M*$11.47M*-$8.00K*
2025-06-30-$17.26M*$15.30M*-$67.00K*
2025-03-31-$22.54M$15.82M-$2.00K-$6.71M
2024-12-31-$19.29M*$26.66M*$0.00*$3.00K*
2024-09-30-$14.66M*-$8.00K*-$1.00K*$0.00*$1.66M*
2024-06-30-$3.01M*$4.00K*-$43.00K*$48.00K*
2024-03-31-$20.71M-$18.50M-$196.00K$245.00K$57.46M*$18.30M
2023-12-31-$15.25M*$10.23M*-$52.00K*$0.00*
2023-09-30-$17.58M*$6.57M*$117.00K*
2023-06-30-$11.03M*-$22.25M*
2023-03-31-$26.84M-$99.39M-$126.23M
2022-12-31-$17.39M*-$1.86M*$0.00*
2022-09-30-$20.56M*-$4.27M*$6.00K*
2022-06-30-$23.71M*-$129.00K*$1.00K*
2022-03-31-$27.68M-$146.00K$176.00K-$27.65M
2021-12-31-$12.17M*$0.00*$153.00K*$154.75M*
2021-09-30-$7.29M*$0.00*-$1.71M*
2021-06-30$2.86M*-$371.00K*-$682.00K*
2021-03-31-$18.73M-$219.00K$151.53M*$132.58M
2020-12-31-$3.17M*$0.00*$0.00*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55